The estimated Net Worth of Grady Iii Grant is at least $72 dollars as of 1 June 2024. Grady Grant owns over 88 units of Aptevo Therapeutics Inc stock worth over $71 and over the last 8 years Grady sold APVO stock worth over $0.
Sign up
Grady Grant APVO stock SEC Form 4 insiders trading
Grady has made over 4 trades of the Aptevo Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Grady exercised 88 units of APVO stock worth $32 on 1 June 2024.
The largest trade Grady's ever made was buying 10,000 units of Aptevo Therapeutics Inc stock on 21 May 2019 worth over $8,000. On average, Grady trades about 1,074 units every 141 days since 2016. As of 1 June 2024 Grady still owns at least 198 units of Aptevo Therapeutics Inc stock.
You can see the complete history of Grady Grant stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Grady Grant's mailing address?
Grady's mailing address filed with the SEC is 2401 4TH AVENUE, SUITE 1050, SEATTLE, WA, 98121.
Insiders trading at Aptevo Therapeutics Inc
Over the last 8 years, insiders at Aptevo Therapeutics Inc have traded over $17,157,676 worth of Aptevo Therapeutics Inc stock and bought 1,998,342 units worth $25,387,921 . The most active insiders traders include Kevin Ctang Capital Managem..., Fuad El Hibri und Daniel Abdun Nabi. On average, Aptevo Therapeutics Inc executives and independent directors trade stock every 38 days with the average trade being worth of $22,185. The most recent stock trade was executed by So Young Kwon on 8 August 2024, trading 213 units of APVO stock currently worth $77.
What does Aptevo Therapeutics Inc do?
aptevo therapeutics is a biotech company primarily focused on bringing novel oncology and hematology therapeutics to market. we leverage the innovative adaptir™ platform technology, a unique approach to cancer immunotherapy, to improve outcomes for cancer patients. based in seattle, washington, the company is proud of its empowering work environment, entrepreneurial culture, and proprietary platform technology. as a result, aptevo has been able to attract some of the most innovative minds in the field. many of our team members have notable experience with other pioneering biotech companies including trubion, zymogenetics, immunex, dendreon, and vlst. at aptevo therapeutics, our core values of ownership and collaboration—combined with a history of innovation, dedication, and development—are positioning aptevo therapeutics to develop the science of what’s next in biotechnology.
What does Aptevo Therapeutics Inc's logo look like?
Complete history of Grady Grant stock trades at Aptevo Therapeutics Inc
Aptevo Therapeutics Inc executives and stock owners
Aptevo Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Marvin L. White,
Pres, CEO & Director -
Jeffrey G. Lamothe,
Sr. VP, CFO & Treasurer -
Dr. Jane A. Gross,
Sr. VP & Chief Scientific Officer -
Dr. Fatih M. Uckun M.D., Ph.D.,
Chief Clinical Advisor & Consultant -
SoYoung Kwon J.D., LL.M.,
Sr. VP, Gen. Counsel, Corp. Affairs & HR -
Censia Pottorf,
VP of HR -
Heather Boussios,
Acting Gen. Counsel & Assistant Sec. -
Stacey Jurchison,
Sr. Director of Investor Relations & Corp. Communications -
Scott C Stromatt,
Chief Medical Officer and SVP -
Fuad El Hibri,
Director -
Bio Solutions Inc. Emergent,
10% owner -
Daphne Taylor,
SVP, CFO -
Zsolt Harsanyi,
-
John Niederhuber,
-
Marvin L White,
President and CEO -
Daniel Abdun Nabi,
-
Grady Iii Grant,
-
Shawnte Mitchell,
SVP, GC and Corporate Affairs -
Michael Adelman,
SVP, Commercial Operations -
Jeffrey G. Lamothe,
EVP, COO -
Jane A Gross,
SVP & Chief Scientific Officer -
Randy Joe Maddux,
SVP of Operations, CMO -
Barbara Lopez Kunz,
-
So Young Kwon,
SVP, GC, BD & Corp Affairs -
Kevin Ctang Capital Managem...,